Lipocine (LPCN) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lipocine (LPCN) has outperformed TScan Therapeutics (TCRX) over the past year, losing 38.9% versus a loss of 88.5%. Over five years, LPCN leads with a -90.0% price change compared with -96.6% for TCRX. Lipocine is the larger company by market cap ($15.9 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LPCN | TCRX |
|---|---|---|
| Share price | $1.93 | $0.2282 |
| Market cap | $15.91M | $15.47M |
| 1-day change | -12.27% | -17.59% |
| YTD return | -75.97% | -77.18% |
| 1-year return | -38.92% | -88.47% |
| 5-year return | -89.95% | -96.62% |
| EPS (TTM) | $-1.85 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.37 | $2.57 |
| 52-week low | $1.81 | $0.224 |
| Distance from 52-week high | -84.40% | -91.12% |
| Analyst consensus | none | hold |
| Avg. price target upside | +159.07% | +338.21% |
| Average volume | 1.72M | 783.59K |
| Shares outstanding | 8.24M | 63.50M |
| Employees | 14 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LPCN has outperformed TCRX by 49.6 percentage points over the past year.
About Lipocine
LPCN stock →Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
LPCN vs TCRX FAQ
Which is bigger, Lipocine or TScan Therapeutics?
Lipocine (LPCN) is larger, with a market capitalization of $15.91M compared with $15.47M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, LPCN or TCRX?
LPCN returned -38.92% over the past 12 months, compared with -88.47% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Lipocine and TScan Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Lipocine and Biotechnology: Biological Products (No Diagnostic Substances) for TScan Therapeutics.